Infusion Center Working Capital: Financing Buy-and-Bill Drugs
Infusion center working capital is the cash a center needs to keep operating while it waits to be paid. In most medical practices, that gap is driven by payroll and rent. In an infusion center, it is driven by drugs. The center buys expensive medications, administers them, submits claims and then waits for reimbursement, often while already purchasing the next round of inventory.
This article explains why buy-and-bill strains cash flow, how to estimate working capital needs and what financing options may help. Reimbursement and billing rules vary by state and payer, and nothing here is legal, tax, billing or compliance advice.
How Buy-and-Bill Creates a Cash Gap
Under buy-and-bill, the center takes on the financial risk of the drug. The sequence typically looks like this:
- The center purchases the drug from a distributor, often on short payment terms
- The patient receives the infusion after prior authorization is confirmed
- The center submits a claim for the drug and the administration services
- The payer processes the claim, which can take time and may involve denials or requests for information
- Payment arrives, sometimes long after the distributor invoice was due
When the center is growing, the gap widens, because each new patient means more inventory purchased before any of it is reimbursed.
Why Infusion Center Working Capital Needs Are Larger Than Expected
Several factors can make the cash gap bigger than owners plan for:
- High drug costs: specialty biologics can cost far more per dose than the administration fee the center earns
- Denials and underpayments: a denied claim on an expensive drug can tie up significant cash
- Prior authorization delays: scheduling issues can leave purchased inventory sitting on the shelf
- Payer mix: different payers pay on different timelines
- Growth: adding chairs, referral sources or a new location increases inventory needs
Margin pressure from lower-cost alternatives can also change how much cash each infusion generates. Our article on biosimilars and infusion center margins explains how that affects cash flow and underwriting.
Estimating How Much Working Capital You Need
A practical estimate starts with the center’s own data. Owners and their accountants can review:
- Average monthly drug purchases and distributor payment terms
- Average time from infusion to payment, by payer
- Denial and underpayment patterns
- Monthly payroll, rent and debt payments
- Planned growth in patient volume or new therapies
Mapping these items month by month shows the low point in the cash cycle. Working capital should cover that low point with a cushion for surprises, such as a large denial or a payer processing delay.
Financing Options for Infusion Center Working Capital
Depending on the center’s history and financial strength, options may include:
- Revolving lines of credit: the center draws funds to pay for drugs and repays as claims are collected, which can match the cash cycle
- Term working capital loans: a lump sum repaid over time, sometimes used to build a permanent cash reserve
- Working capital within a larger loan: acquisitions and expansions may include a working capital component, subject to program rules and lender review
- SBA 7(a) loans: may be used for working capital in some cases, depending on the business, use of proceeds, program rules and lender review
Our overview of working capital solutions describes these structures in more detail.
What Lenders Look For
Lenders reviewing an infusion working capital request typically want to understand:
- Historical cash flow after drug costs
- Accounts receivable aging and collection history
- Payer mix and any concentration with one payer
- Inventory management and purchasing practices
- Existing debt and how the new facility fits
Centers with clean financial reporting and a clear explanation of their cash cycle are often better positioned. Every loan is subject to approval, and nothing here is a commitment to lend.
Operational Steps That Ease the Gap
Financing is one tool. Operational discipline is another. Centers may reduce strain by:
- Confirming authorization and benefits before purchasing high-cost doses
- Monitoring denials closely and working with qualified billing professionals on appeals
- Avoiding excess inventory on slow-moving drugs
- Reviewing distributor terms periodically
- Tracking collections by payer so delays are spotted early
When Short-Term Debt Becomes a Burden
Some centers cover drug costs with high-cost short-term financing when cash runs tight. Over time, frequent payments on that debt can make the cash gap worse. Owners in that position may want to explore whether a longer-term structure could help. Our article on infusion center refinance options explains how restructuring may work and what lenders consider.
Planning for New Centers and Interest Rate Changes
Startups face the cash gap from the first infusion, before any collection history exists. Our guide to the cost to open an infusion center explains why ramp-up reserves belong in the initial budget.
Variable-rate lines of credit can also become more or less expensive as rates move. Our article on how interest rate decisions affect infusion therapy financing explains what owners may want to consider.
Final Thoughts
Infusion center working capital is not a side issue. In a buy-and-bill model, it is central to how the business operates and grows. Owners who understand their cash cycle, plan for denials and growth and arrange financing before they need it are often better prepared to serve patients without running short.
US Medical Funding helps infusion center owners arrange working capital and lines of credit. Learn more about our infusion therapy working capital and lines of credit and our full range of infusion therapy financing options.
